Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Protocol Amendment History 4 changes
notable Trial sites expanded: 90 -> 101 locations 2026-06-27
notable Trial sites expanded: 82 -> 90 locations 2026-06-02
notable Trial sites expanded: 64 -> 82 locations 2026-05-05
notable Trial sites expanded: 51 -> 64 locations 2026-04-04
Trial Details
NCT Number NCT06979336
Lead Sponsor Genentech, Inc.
Conditions Ulcerative Colitis
Enrollment 224 participants
Start Date 2025-09-29
Primary Completion 2027-08-25 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28